Pharmacyte Biotech, Inc. (PMCB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pharmacyte Biotech, Inc., a Nevada corporation, on April 13, 2022, covering events occurring on April 7, 2022, and April 12, 2022. The company is listed on The Nasdaq Capital Market under the symbol PMCB.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on executive compensation adjustments and regulatory compliance status.
Material Changes
- Executive Compensation Increases: On April 7, 2022, the Board approved retroactive salary increases effective January 1, 2022:
- CEO Kenneth L. Waggoner: Increased from $375,000 to $520,000 per annum.
- CFO Carlos Trujillo: Increased from $275,000 to $380,000 per annum.
- Nasdaq Compliance: On April 12, 2022, Nasdaq Staff confirmed the Company complies with the independent director requirement (Listing Rule 5605) following the appointment of Dr. Matthias Löhr to the Board.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding future operations or financial performance. The primary focus is the formalization of executive pay and the resolution of a listing compliance matter.
Key Facts for Investor Verification
- Verify the impact of the increased executive compensation on the company's operating expenses and cash burn rate in upcoming quarterly reports.
- Confirm the continued listing status on Nasdaq following the April 12, 2022 compliance notification.
- Review the April 5, 2022 Form 8-K referenced in the filing for details regarding the appointment of Dr. Matthias Löhr.